Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06951737

Enrollment

120

Registered

2025-04-30

Start date

2022-10-02

Completion date

2024-10-02

Last updated

2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF), Diabetes Mellitus

Brief summary

Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patients \> 18 years and \< 90 years, * Patient diagnosed with DM * Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm

Exclusion criteria

* patient who are not suitable for anticoagulant use, * have thyroid dysfunction, * glomerular filtration rate ≤ 25 ml/min/1.73 m², * patients whose sinus rhythm cannot be achieved with electrical cardioversion, * malignancy patients, * patients with acute or chronic inflammatory disease, * patients with peripheral artery disease, * patients with pacemakers, * patients with advanced valve stenosis or insufficiency, * patients who have had coronary bypass surgery, * patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation recurrence	six month

Countries

Turkey (Türkiye)

Outcome results